Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IAVI statement on new analysis of STEP large-scale AIDS vaccine trial

12.11.2007
Further analysis needed to understand why vaccine was not effective; support for AIDS vaccines now more important than ever

The International AIDS Vaccine Initiative (IAVI) issued the following statement from its President and CEO, Dr. Seth Berkley, following the release of the first analysis of the entire study population from a late-stage AIDS vaccine trial, known as the STEP study. The analysis confirmed an earlier analysis of data on half of the 3,000 trial volunteers, released Sept. 21, that concluded the vaccine candidate, manufactured by Merck & Co., was not efficacious.

The Merck candidate neither prevented HIV infection nor lessened the amount of virus in those who became infected. According to the trial co-sponsors, Merck and the HIV Vaccines Trial Network (HVTN), the new analysis suggests that those who received the vaccine, which cannot cause HIV infection, might have an increased susceptibility to acquiring HIV. Volunteers who had prior natural exposure to the Ad5 vector that was used in the vaccine might be particularly susceptible, the trial sponsors said. Responding to the news, which was announced at a special open scientific session at a meeting of the HVTN in Seattle Nov. 7, IAVI’s Dr. Berkley said:

“It’s disappointing that the Merck candidate didn’t work, but it’s important to bear in mind that this was one trial, of one candidate. It is as vital as ever to find an AIDS vaccine, and the effort will continue.

“It took 47 years after the polio virus was discovered before a vaccine was developed. Chicken pox took 42 years. Rotavirus, which causes diarrheal disease, took 33. HIV was discovered 24 years ago and we’ve only had a serious AIDS vaccine effort for about a decade, with only two candidates tested for efficacy. History tells us it takes a long time to develop a vaccine, but it also tells us it’s the only way to eliminate a plague like AIDS. No viral epidemic has been defeated without a vaccine.

“It’s also vital that everybody keeps straight what we know and what we don’t know. We know the Merck vaccine didn’t work. We don’t know why. We know that more people who got the Merck candidate than got the placebo wound up becoming HIV infected. We don’t know if that had anything to do with the candidate or not. Given that the trend didn’t rise to statistical significance, it could have been chance. And if the vaccine was a factor, we don’t know why.

“Our view is that the results of the Merck trial will require a great deal more study before larger lessons can be drawn from them for the larger AIDS vaccine field.

“In the meantime, the news should be absorbed with some perspective. The world owes a debt of gratitude to the STEP trial’s sponsors and, most of all, to the study volunteers. Though the Merck candidate failed, the trial did not. The contribution of the volunteers was not in vain. As a result of their dedication, the field will have new data that will inform future vaccine design, help with the prioritization of candidates in the pipeline and guide decisions on how to best proceed with ongoing and upcoming trials.

“It is also important to recognize that the failure of the Merck product to prevent HIV infection is not unexpected. Merck’s candidate, like nearly all vaccine candidates now in the pipeline, was designed to activate the T-cell arm of the immune system. T-cells work like commando units, travelling through the body, seeking out pathogen-infected cells, which they then kill. Because T-cells only attack cells that are already infected, many scientists, including those at IAVI, think T-cell vaccines are unlikely to protect individuals from becoming infected. It’s more likely T-cell vaccines will reduce the amount of virus in people who, once vaccinated, become infected. In the event, the Merck vaccine did not achieve either result.

“Because of this limitation of T-cell vaccines, some scientists in the field, including those at IAVI, in recent years have shifted more resources toward discovery of next-generation candidates, including those that would activate the antibody arm of the immune system. Antibodies act like the body’s border guards, stopping pathogens from entering the body, and thus preventing infection.

“Whatever lessons the STEP trial eventually teaches us, one thing is certain: the need for a vaccine has never been greater. The arithmetic hasn’t changed. About 39 million people are HIV infected; three million die annually of AIDS. Antiretroviral therapies prolong the lives of those who become infected, but for every person who is put on ARV treatment, there are six new HIV infections. UNAIDS recently estimated that to fulfil the G8’s goal of providing a comprehensive AIDS response, including prevention, treatment and care, to everyone in the developing world who needs it would cost at least $45 billion a year by 2015, more than five times what is being spent today. Spending on AIDS would have to go from a tenth of all overseas development to a third, jeopardizing other development goals. And although ARVs ease the suffering of those who are sick, they will not end the epidemic. Only a vaccine holds out the hope of eliminating AIDS.

“And there are sound scientific reasons to believe we can develop a vaccine against AIDS. The human immune system, it turns out, is better at fighting HIV than we’d originally thought. Most people suppress the virus for many years before developing AIDS. A small number never contract the virus despite repeated exposure. Others are infected but have not developed AIDS. What’s more, vaccine studies in non-human primates, our closest relatives, show that infection can be prevented entirely. With such strong evidence in humans and in animals, scientists think a vaccine is possible.

“Developing a truly effective, preventive vaccine has been, and will continue to be, an extremely challenging scientific goal. But given the human stakes, we have no choice but to redouble our efforts to realize that goal.

Rachel Steinhardt | EurekAlert!
Further information:
http://www.iavi.org

More articles from Studies and Analyses:

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

nachricht First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Designer cells: artificial enzyme can activate a gene switch

22.05.2018 | Life Sciences

PR of MCC: Carbon removal from atmosphere unavoidable for 1.5 degree target

22.05.2018 | Earth Sciences

Achema 2018: New camera system monitors distillation and helps save energy

22.05.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>